Wellington Management Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Wellington Management Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,472,043	Closed	-$150M	–	1910
2023 Q2	$150M	Buy	1,472,043 +50,881	+4%	+$4.81M	0.03%	451
2023 Q1	$129M	Sell	1,421,162 -86,720	-6%	-$5.09M	0.03%	482
2022 Q4	$57.3M	Sell	1,507,882 -64,384	-4%	-$2.22M	0.01%	652
2022 Q3	$39.5M	Sell	1,572,266 -2,437,394	-61%	-$67.6M	0.01%	727
2022 Q2	$122M	Sell	4,009,660 -386,879	-9%	-$11.5M	0.02%	489
2022 Q1	$144M	Buy	4,396,539 +143,562	+3%	+$4.26M	0.02%	497
2021 Q4	$112M	Buy	4,252,977 +9,705	+0.2%	+$751K	0.02%	600
2021 Q3	$427M	Sell	4,243,272 -83,196	-2%	-$9.75M	0.07%	255
2021 Q2	$612M	Sell	4,326,468 -29,299	-0.7%	-$3.31M	0.1%	208
2021 Q1	$434M	Buy	4,355,767 +10,043	+0.2%	+$1.17M	0.08%	253
2020 Q4	$537M	Buy	4,345,724 +355,972	+9%	+$46.8M	0.1%	204
2020 Q3	$389M	Buy	3,989,752 +248,053	+7%	+$31M	0.08%	225
2020 Q2	$584M	Buy	3,741,699 +720,775	+24%	+$110M	0.13%	154
2020 Q1	$436M	Buy	3,020,924 +628,250	+26%	+$121M	0.12%	168
2019 Q4	$489M	Buy	2,392,674 +1,877,864	+365%	+$343M	0.1%	194
2019 Q3	$41.3M	Buy	514,810 +10,231	+2%	+$868K	0.01%	768
2019 Q2	$47.6M	Buy	+504,579	New	+$43.6M	0.01%	772

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wellington Management Group's RETA Position: Q3 2023 in Review

Wellington Management Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,472,043 shares — an estimated $150M sold.

Wellington Management Group first reported a position in RETA in Q2 2019 and held it in 17 quarters. The position peaked at $612M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Wellington Management Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Wellington Management Group sold 1,472,043 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $150M.
Wellington Management Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 17 quarters.
Wellington Management Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $612M in Q2 2021.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Wellington Management Group's 13F filing for Q3 2023, filed 14 Nov 2023.